|
시장보고서
상품코드
2008030
PEG화 단백질 시장 : 유형별, 단백질별, 용도별, 최종사용자별, 지역별PEGylated Proteins Market, By Type, By Protein, By Application, By End User, By Geography |
||||||
PEG화 단백질 시장은 2026년에 22억 달러로 추정되고 있으며, 2033년까지 47억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 11.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 22억 달러 |
| 대상 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 11.60% | 2033년 시장 규모 예측 : | 47억 달러 |
PEG화는 화학적 변형을 위해 다양한 형태의 치료용 단백질에 활성 폴리에틸렌글리콜(PEG)을 첨가하는 과정입니다. 이렇게 화학적으로 변형된 치료용 단백질을 PEG화 단백질 치료제라고 합니다. PEG화 단백질 치료제는 암, 혈우병, 류마티스 관절염, 강직성 척추염, 크론병 등 다양한 질환의 치료에 사용되고 있습니다. PEG화는 일부 바이오의약품의 단점을 완화하기 위해 무독성, 비면역성 고분자인 폴리에틸렌글리콜(PEG)을 사용하여 생체 분자를 공유결합으로 변형시키는 것을 말합니다.
폴리에틸렌글리콜(PEG)은 '무해성'과 생체적합성으로 인해 약물전달 및 나노테크놀러지에 자주 사용되고 있습니다. PEG화를 통해 바이오소재 및 입자 전달법이 면역계를 우회하여 순환 수명을 연장할 수 있다는 것은 널리 알려져 있습니다. 그러나 단백질의 PEG화는 복잡한 과정이며, 단백질의 유형와 용도에 따라 다양한 방법을 통해 이루어질 수 있습니다. 비활성 PEG 사슬은 대상 단백질과 공유 결합 또는 비공유 결합으로 복합체를 형성합니다. 또 다른 중요한 단계는 PEG화 단백질의 정제이며, 이는 주로 크로마토그래피나 정전기적 상호작용 또는 분자 크기에 따라 이루어집니다.
시장 역학
시장내 주요 기업의 제품 출시와 같은 비유기적 전략의 채택이 증가하면서 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2020년 2월 노보노디스크는 A형 혈우병 환자 치료제로 미국에서 에스퍼록트(ESPEROCT)를 출시했습니다. A형 혈우병 환자의 출혈을 예방하거나 횟수를 줄이고, 출혈을 치료하고 조절하며, 수술 중 출혈을 관리하는 데 사용되는 반감기가 연장된 재조합 제8인자 보충요법입니다. ESPEROCT는 항혈우병 인자(재조합)이며, 글리코페그화-exei입니다.
본 조사의 주요 특징.
- 이 보고서는 세계 PEG화 단백질 시장에 대한 상세한 분석을 제공하며, 2025년을 기준연도, 예측 기간(2026-2033년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 예측하고 있습니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서에서는 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과 및 전략과 같은 매개 변수를 기반으로 세계의 PEG화 단백질 시장의 주요 업체를 프로파일링합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 등급 향상, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 PEG화 단백질 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 PEG화 단백질 시장 : 유형별, 2026-2033년
제5장 세계의 PEG화 단백질 시장 : 단백질별, 2026-2033년
제6장 세계의 PEG화 단백질 시장 : 용도별, 2026-2033년
제7장 세계의 PEG화 단백질 시장 : 최종사용자별, 2026-2033년
제8장 세계의 PEG화 단백질 시장 : 지역별, 2026-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.04.30PEGylated Proteins Market is estimated to be valued at USD 2.2 Bn in 2026 and is expected to reach USD 4.7 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.60% | 2033 Value Projection: | USD 4.7 Bn |
PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals.
Due to its claimed silent qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes.
Market Dynamics
Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei.
Key features of the study
- This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global PEGylated proteins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market
Market Segmentation
- By Type
- Consumables
- Services
- By Protein
- Colony-stimulating factor
- Interferons
- Erythropoietin
- Recombinant factor VII
- Other
- By Application
- Cancer
- Autoimmune Disease
- Hepatitis
- Multiple Sclerosis
- Hemophilia
- Gastrointestinal Disorder
- Others
- By End User
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic Research Institutes
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Biogen Inc
- Pfizer Inc
- UCB S.A.
- Leadiant Biosciences, Inc.
- Amgen Inc.
- Thermo Fisher Scientific Inc.
- Horizon Therapeutics Plc.
- Novo Nordisk A/S
- Hoffmann-La Roche AG
- Bayer AG
- BioMarin
- RedHill Biopharma Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Protein
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pipeline Analysis
- PEST Analysis
4. Global PEGylated Proteins Market, By Type, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Consumables
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Services
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global PEGylated Proteins Market, By Protein, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Colony Stimulating Factor
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Interferon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Erythropoietin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Recombinant Factor VII
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global PEGylated Proteins Market, By Application, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Autoimmune Disease
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Multiple Sclerosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hemophilia
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Gastrointestinal Disorder
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global PEGylated Proteins Market, By End User, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Pharmaceutical and Biotechnology Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Contract Research Organizations
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Academic Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global PEGylated Proteins Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Protein, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026-2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Leadiant Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Horizon Therapeutics Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BioMarin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- RedHill Biopharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
